Search hospitals > South Carolina > Greenville

Prisma Health Cancer Institute - Eastside

Claim this profile
Greenville, South Carolina 29615
Global Leader in Skin Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Uterine Tumors
Conducts research for Cancer
308 reported clinical trials
14 medical researchers
Photo of Prisma Health Cancer Institute - Eastside in GreenvillePhoto of Prisma Health Cancer Institute - Eastside in GreenvillePhoto of Prisma Health Cancer Institute - Eastside in Greenville

Summary

Prisma Health Cancer Institute - Eastside is a medical facility located in Greenville, South Carolina. This center is recognized for care of Skin Cancer, Breast Cancer, Lung Cancer, Uterine Tumors, Cancer and other specialties. Prisma Health Cancer Institute - Eastside is involved with conducting 308 clinical trials across 466 conditions. There are 14 research doctors associated with this hospital, such as Ki Chung, MD, Aniket Saha, Jeffrey K. Giguere, and William J Edenfield, MD.

Area of expertise

1Skin Cancer
Global Leader
Prisma Health Cancer Institute - Eastside has run 114 trials for Skin Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Prisma Health Cancer Institute - Eastside has run 54 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
Stage IV
ER positive

Top PIs

Clinical Trials running at Prisma Health Cancer Institute - Eastside

Breast Cancer
Breast cancer
Skin Cancer
Cancer
Lung Cancer
Uterine Tumors
Acute Myeloid Leukemia
Non-Small Cell Lung Cancer
Bladder Cancer
Lymphoma
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Prisma Health Cancer Institute - Eastside?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security